stabilitech.com Report : Visit Site

Technical data of the stabilitech.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host stabilitech.com. Currently, hosted in Bulgaria and its service provider is GetClouder EOOD .

the related websites

autifony.com mrc.ac.uk manufacturingchemist.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

home platform technology therm-sb applications next generation biopharmaceucticals oral viral vectored proteins next generation vaccines antigen sparing accelerated immunity cold chain enhancement thermostability alum freeze protection pipeline pipeline vzv product exemplar multi-strain influenza vaccine novel oral protein therapeutic butyryl-cholinesterase zika virus news the company board of directors scientific advisory board partnering privacy policy contact investor relations general meetings audited accounts shareholder updates select page stabilitech biopharma redefining the way we make and take vaccines . platform licensing orapro™ antigen sparing therm-sb orapro™ imagine a world where all vaccines were taken as a capsule – no needles, long-term thermal stability, reduced need for healthcare professionals, global efficacy. is a ‘plug-and-play’ oral delivery vaccine platform. it effectively delivers non-replicating viral vectors to the gi tract to eliciting effective immunity against infectious diseases but not the viral vector. stabilitech is using orapro™ to develop the world’s first oral zika vaccine. stabilitech is now using orapro™ to develop oral vaccines for ‘blockbuster’ indications, including orapro-hsv-2 to address the herpes simplex virus 2, which currently affects 400 million people. the herpes market will be worth $9bn in 2018. more about orapro™ & pipeline developments omniflu™ is the world’s first omni-valent influenza vaccine. it is capable of delivering 15 strains in a single dose whereas current products can only deliver 3 or 4. by increasing the strains per dose, omniflu™ can reduce strain selection mismatches (which recently have been running as high as 50%) thereby increasing the immunity of patients and saving lives. it also reduces costs for vaccine manufacturers and healthcare systems. omniflu™ represents a potential paradigm shift in the fight against influenza and a breakthrough in a market forecast to be worth $4.3bn by 2025. more about omniflu™ learn more novel oral protein therapeutic learn more multi-strain influenza vaccine learn more vzv product exempler learn more reduce antigen requirement by up to 99% learn more thermally stable vaccines learn more faster onset of immunity using less vaccine news stabilitech biopharma announces cancer immunotherapy partnership with oncolys biopharma by wayne | may 23, 2018 | news | 0 comments stabilitech biopharma ltd (“stabilitech”), a uk biotechnology company developing next generation vaccines and biopharmaceuticals, is pleased to announce an exclusive, worldwide license agreement with oncolys biopharma inc. (“oncolys”) of japan. the in-licensing deal will explore the use of stabilitech’s proprietary virus stability platform technology, therm-sb™, to support oncolys’ viroimmunotherapy pipeline led by telomelysin ® stabilitech will grant oncolys a license in relation to therm-sb, in return for which it will be entitled to receive undisclosed milestone fees and royalties according to development stages and sales performances. oncolys aims to utilise the therm-sb thermostability technology to improve the usability of its existing oncolytic virus pipeline, in response to demand in clinical settings, and expects to apply the platform to next generation candidates currently under development for systemic treatment. “we are delighted to partner with an international business of oncolys’ stature to demonstrate further the strength and versatility of therm-sb, this time in cancer treatment.”said stabilitech ceo, wayne channon. “our companies share a mission to bring innovation and technology to existing treatments for serious conditions with unmet needs and we are confident that our relationship will be fruitful.” therm-sb has been applied successfully to a number of biopharmaceuticals and other temperature labile biological materials. the platform is based on a formulation of non-toxic small molecules that are mixed with the virus/vaccine during the fill-finish process. “our therm-sb platform will change the way virotherapy products are stored and handled. no more cold-chain logistics for manufacturers, or product wastage for temperature excursions within hospitals.,” said elliot bland, ph.d., business development director at stabilitech. “we have seen success with therm-sb on all viruses to date: vaccines, gene therapy vectors and virotherapies.we look forward to continuing that success with telomelysinand others in the oncolys pipeline.” stabilitech wins £2m innovate uk funding for oral zika vaccine by wayne | feb 6, 2018 | news | 0 comments 6 february 2018 stabilitech wins second round of innovate uk funding for oral zika vaccine stabilitech biopharma ltd (“stabilitech”), a uk biotechnology company developing next generation vaccines and biopharmaceuticals, has been awarded further funding of £1.98m from innovate uk to develop its oral zika virus vaccine to first-in-human ready by 2020. government agency innovate uk, investing through its small business research initiative (sbri), first supported stabilitech’s oral zika vaccine programme in 2016 under round one of the vaccines for global epidemics scheme. backed by the first funding round, stabilitech demonstrated protective systemic immunity from oral vaccination in non-clinical models. the vaccine immunity appeared equivalent to natural immunity gained from prior exposure to the active zika virus. vaccine candidates were shipped from the uk to brazil without a cold-chain and remained efficacious, demonstrating stabilitech’s renowned thermal stability technologies. “we are delighted to have received this further funding from innovate uk to take our zika development to the next level.” said stabilitech ceo, wayne channon. “our aim is to use our technology to develop self-administrable oral vaccines that can be easily distributed on a worldwide basis. the zika virus, which can cause devastating effects if caught during pregnancy, and for which there is no vaccine available, is an excellent target for our platform.” stabilitech’s zika vaccine is being developed on the company’s orapro™ platform, producing thermally stable capsules delivering the vaccine to the intestine. upon reaching the gi tract, the capsule releases viral-vectors engineered to deliver a dna payload to transduce zika virus antigens from gi cells, ultimately inducing protective systemic immunity. “our oral zika vaccine provides protection against two zika virus antigens, better mimicking natural immunity. additionally our vaccine also reduces the requirement of cold-chain logistics, the use of needles and the level of involvement of healthcare professionals during vaccination campaigns,” said elliot bland, ph.d., director of business development at stabilitech. “we look forward to accelerating our development towards the clinic with this new funding from innovate uk.” « older entries recent posts stabilitech biopharma announces cancer immunotherapy partnership with oncolys biopharma 23/05/2018 stabilitech wins £2m innovate uk funding for oral zika vaccine 06/02/2018 recent research alliances – zoetis 16/10/2016 gsk collaboration, option and license agreement 16/10/2016 stabilitech limited unit 6, sovereign business park albert drive burgess hill bh15 9ty united kingdom view map telephone: +44 1444 241911 [email protected] © stabilitech limited designed by elegant themes | powered by wordpress

URL analysis for stabilitech.com

https://www.stabilitech.com/protein-expression-and-delivery
https://www.stabilitech.com/protein-expression-and-delivery/
https://www.stabilitech.com/butyryl-cholinesterase/
https://www.stabilitech.com/accelerated-immunity/
https://www.stabilitech.com/antigen-sparing/
https://www.stabilitech.com/zika-virus/
https://www.stabilitech.com/partnering/
https://www.stabilitech.com/thermostability-3/
https://www.stabilitech.com/stabilitech-biopharma-announces-cancer-immunotherapy-partnership-with-oncolys-biopharma/
https://www.stabilitech.com/recent-research-alliances-zoetis/
https://www.stabilitech.com/gsk-collaboration-option-and-license-agreement/
https://www.stabilitech.com/news/
https://www.stabilitech.com/stabilitech-wins-2m-innovate-uk-funding-for-oral-zika-vaccine/
https://www.stabilitech.com/accelerated-immunity/
https://www.stabilitech.com/platform-technology/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: stabilitech.com
Registrar URL: http://www.godaddy.com
Registrant Name: Jeff Drew
Registrant Organization: Stabilitech Ltd
Name Server: NS1.UK6.SITEGROUND.EU
Name Server: NS2.UK6.SITEGROUND.EU
DNSSEC: unsigned

For complete domain details go to:
http://who.godaddy.com/whoischeck.aspx?domain=stabilitech.com

The data contained in GoDaddy.com, LLC's WhoIs database,
while believed by the company to be reliable, is provided "as is"
with no guarantee or warranties regarding its accuracy. This
information is provided for the sole purpose of assisting you
in obtaining information about domain name registration records.
Any use of this data for any other purpose is expressly forbidden without the prior written
permission of GoDaddy.com, LLC. By submitting an inquiry,
you agree to these terms of usage and limitations of warranty. In particular,
you agree not to use this data to allow, enable, or otherwise make possible,
dissemination or collection of this data, in part or in its entirety, for any
purpose, such as the transmission of unsolicited advertising and
and solicitations of any kind, including spam. You further agree
not to use this data to enable high volume, automated or robotic electronic
processes designed to collect or compile this data for any purpose,
including mining this data for your own personal or commercial purposes.

Please note: the registrant of the domain name is specified
in the "registrant" section. In most cases, GoDaddy.com, LLC
is not the registrant of domain names listed in this database.

  REGISTRAR GODADDY.COM, LLC

  REFERRER http://www.godaddy.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =stabilitech.com

  PORT 43

  SERVER whois.godaddy.com

  ARGS stabilitech.com

  PORT 43

  TYPE domain

DOMAIN

  NAME stabilitech.com

NSERVER

  NS1.UK6.SITEGROUND.EU 185.123.97.170

  NS2.UK6.SITEGROUND.EU 77.104.128.180

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientRenewProhibited https://icann.org/epp#clientRenewProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

  CHANGED 2016-08-15

  CREATED 2002-07-27

  EXPIRES 2022-07-27

OWNER

ADMIN

TECH

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .